Grufity logoGrufity logo

CERS

3.70USD-0.16(-4.15%)Market Closed

Cerus Corp

Market Summary

USD3.70-0.16Market Closed
-4.15%

CERS Stock Price

RSI Chart

Valuation

Market Cap

651.7M

Price/Earnings

-15.43

Price/Sales

3.91

Price/Cashflow

-22.01

MarketCap/EBT

-15.54

Price/Sales

Profitability

EBT Margin

-26.29%

Return on Equity

-55.73%

Return on Assets

-19.51%

Fundamentals

Revenue

Revenue (TTM)

159.5M

Earnings

Earnings (TTM)

-42.2M

Earnings Y/Y

45.39%

Earnings Q/Q

31.71%

Price Action

52 Week Range

3.257.20
(Low)(High)

Last 7 days

-3.6%

Last 30 days

0.5%

Last 90 days

-10.8%

Trailing 12 Months

-47.0%

Financial Health

Current Ratio

2.08

Investor Care

Shares Dilution (1Y)

3.18%

Diluted EPS (TTM)

-0.24

Peers (Alternatives to Cerus)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-9.62% 40.13%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
-0.86% -5.85%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
7.57% -20.23%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
0.88% 0.27%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
1.46% 13.53%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
6.93% -30.81%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
5.68% 11.07%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
16.86% -20.83%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-17.36% 8.54%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-26.60% -68.24%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
13.24% 18.65%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
-7.32% -10.12%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.20% -15.61%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-9.99% -42.69%
-16.43
2.57
-8.79% -175.19%

Financials for Cerus

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2021Q42021Q32021Q22021Q12020Q4
Revenue26.1%160127121116114
Operating Expenses1.3%145143140
  S&GA Expenses4.2%817874
Earnings Before Taxes8.8%-54.06-59.30-61.00
Net Income8.8%-54.37-59.64-61.34
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-2.5%216222237219223
  Current Assets-4.7%165173187178186
    Cash Equivalents-15.8%3238497859
  Inventory-2.7%2829272931
  Net PPE-3.9%1112121313
  Goodwill0%11111
Liabilities-1.3%140141152138139
  Current Liabilities18.9%7967796566
Shareholder's Equity-4.6%7679858084
  Retained Earnings-0.9%-985.01-976.63-964.34-955.22-942.79
  Additional Paid-In Capital0.5%1,0631,0571,0491,0351,027
Shares Outstanding0.7%176174174172171
Minority Interest-0.6%1111-
Float-862----
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations21.9%-29.60-37.92-33.92-41.60-40.21
  Share Based Compensation-3.2%2425242221
Cashflow From Investing-18697.6%-15.41-0.08136133
Cashflow From Financing0.4%1919343030

Risks

What is the probability of a big loss on CERS?

100%


Probability that Cerus stock will be more than 20% underwater in next one year

84.6%


Probability that Cerus stock will be more than 30% underwater in next one year.

48.5%


Probability that Cerus stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CERS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Cerus was unfortunately bought at previous high price.

Returns

Cumulative Returns on CERS

1.4%


10-Year Cumulative Returns

-5.9%


7-Year Cumulative Returns

-1.1%


5-Year Cumulative Returns

-5.2%


3-Year Cumulative Returns

What are the long-term rolling returns for CERS?

FIve years rolling returns for Cerus.

Which funds bought or sold CERS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Capital Impact Advisors, LLC
NEW
-
49,000
49,000
0.05%
2022-11-21
Parallax Volatility Advisers, L.P.
ADDED
244.01
100,000
175,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.12
-386,000
793,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-3,000
-
-%
2022-11-15
Verdence Capital Advisors LLC
ADDED
3.58
-35,000
84,000
0.01%
2022-11-15
CreativeOne Wealth, LLC
ADDED
2.01
-40,000
92,000
0.01%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
COLONY GROUP LLC
UNCHANGED
-
-154,000
328,000
0.01%
2022-11-15
Tamarack Advisers, LP
ADDED
21.25
-1,850,000
8,730,000
5.13%
2022-11-15
JANE STREET GROUP, LLC
ADDED
203.77
114,000
221,000
-%

1–10 of 40

Latest Funds Activity

Are funds buying CERS calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CERS

Cerus News

ETF Daily News

Bridgewater Associates LP Acquires 28896 Shares of Cerus Co. (NASDAQ:CERS).15 hours ago

Thehour.com

CERS Fair Value

Recent SEC filings of Cerus

View All Filings
Date Filed Form Type Document
Nov 14, 2022
4
Insider Trading
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for CERS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-10
Swisher Daniel N JR
ACQUIRED
39,875
3.19
12,500
-
2022-11-10
Swisher Daniel N JR
SOLD
-48,875
3.91
-12,500
-
2022-08-15
Menard Chrystal
SOLD
-51,800
5.18
-10,000
Chief Legal Officer
2022-08-09
Benjamin Richard J
SOLD
-51,194
5.1194
-10,000
Chief Medical Officer
2022-07-01
Shan Hua
ACQUIRED
-
-
29,886
-
2022-06-01
NACHTSHEIM JAMI K
ACQUIRED
-
-
20,454
-
2022-06-01
Swisher Daniel N JR
ACQUIRED
-
-
20,454
-
2022-06-01
Witney Frank
ACQUIRED
-
-
20,454
-
2022-06-01
MOORE TIMOTHY L.
ACQUIRED
-
-
20,454
-
2022-06-01
SCHULZE GAIL
ACQUIRED
-
-
20,454
-

1–10 of 50

William M. Greenman
290
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CERS Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:    
Research and development$ 16,220$ 15,288$ 45,493$ 48,119
Selling, general and administrative19,90820,35760,17559,285
Total operating expenses36,12835,645105,668107,404
Loss from operations(7,447)(11,126)(24,130)(41,974)
Non-operating expense, net:    
Foreign exchange gain (loss)234(164)(68)(442)
Interest expense(1,406)(1,279)(4,134)(3,589)
Other income (expense), net165205(647)998
Total non-operating expense, net(1,007)(1,238)(4,849)(3,033)
Loss before income taxes(8,454)(12,364)(28,979)(45,007)
Provision for income taxes6773221248
Net loss(8,521)(12,437)(29,200)(45,255)
Net loss attributable to noncontrolling interest(39) (45) 
Net loss attributable to Cerus Corporation$ (8,482)$ (12,437)$ (29,155)$ (45,255)
Net loss per share attributable to Cerus Corporation    
Basic$ (0.05)$ (0.07)$ (0.17)$ (0.27)
Diluted$ (0.05)$ (0.07)$ (0.17)$ (0.27)
Weighted average shares outstanding:    
Basic177,236171,904176,231170,666
Diluted177,236171,904176,231170,666
Product    
Revenue$ 39,571$ 36,131$ 118,014$ 90,994
Cost of revenue17,66217,58255,45644,000
Gross profit21,90918,54962,55846,994
Government Contract    
Revenue$ 6,772$ 5,970$ 18,980$ 18,436

CERS Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 28,875$ 48,759
Short-term investments74,95280,600
Accounts receivable28,15125,129
Current inventories, net28,32926,793
Prepaid and other current assets4,4245,821
Total current assets164,731187,102
Non-current assets:  
Property and equipment, net10,64712,208
Operating lease right-of-use assets12,89012,971
Goodwill1,3161,316
Restricted cash1,9982,285
Other assets23,82121,617
Total assets215,403237,499
Current liabilities:  
Accounts payable29,81535,608
Accrued liabilities20,05925,673
Debt – current42,38014,697
Operating lease liabilities – current2,0111,905
Deferred product revenue754673
Total current liabilities95,01978,556
Non-current liabilities:  
Debt – non-current27,35754,724
Operating lease liabilities – non-current15,70316,260
Other non-current liabilities3,2512,342
Total liabilities141,330151,882
Commitments and contingencies
Stockholders' equity:  
Common stock177174
Additional paid-in capital1,069,6291,048,936
Accumulated other comprehensive loss(3,189)(149)
Accumulated deficit(993,497)(964,342)
Total Cerus Corporation stockholders' equity73,12084,619
Noncontrolling interest953998
Total liabilities and stockholders' equity$ 215,403$ 237,499